spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  SCLC 

 HSMN NewsFeed - 3 Feb 2025
CHMP Issues Positive Opinion for Subcutaneous RYBREVANT(R)(amivantamab) Co-Formulated with ENHANZE(R) for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 17 Jan 2025
FDA Approves LUMAKRAS(R) (Sotorasib) in Combination with Vectibix(R) (Panitumumab) for Chemorefractory KRAS G12C-Mutated Metastatic Colorectal Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 11 Dec 2024
Ariceum Therapeutics and NorthStar Medical Radioisotopes Announce Supply Agreement for Therapeutic Radioisotope Actinium-225
Biopharmaceuticals Oncology
 HSMN NewsFeed - 24 Oct 2024
Pillar Biosciences Receives CPT(R) Code for FDA Approved oncoReveal(TM) CDx Pan-Cancer Solid tumor IVD Kit
Diagnostics Oncology Reimbursement
 HSMN NewsFeed - 20 Aug 2024
RYBREVANT(R) (amivantamab-vmjw) Plus LAZCLUZE(TM) (lazertinib) Approved in the U.S. as a First-line Chemotherapy-free Treatment for Patients with EGFR-mutated Advanced Lung Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 27 Feb 2024
Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-520
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 2 Jan 2024
Allorion Therapeutics Announces Exclusive Option and Global License Agreement for Novel Preclinical-Stage EGFR L858R Allosteric Inhibitor Program with AstraZeneca
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 26 Dec 2023
Amgen Provides Regulatory Update on Status of Lumakras(R) (Sotorasib)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 10 Nov 2023
Mirati Therapeutics Receives Positive Opinion from CHMP for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation Following a Re-Examination Procedure
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 20 Jul 2022
Nuvalent Announces Leadership Promotions
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 8 Jun 2022
Ariceum Therapeutics Launches with EUR 25M Series A to Advance Lead Asset, Satoreotide, for the Treatment of Low- and High-Grade Neuroendocrine Cancers
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 27 May 2022
Accord Healthcare Adds Pemetrexed Lyo. Injection to Generic Drug Portfolio
Biopharmaceuticals Generics Oncology Product Launch
 HSMN NewsFeed - 18 May 2022
Theseus Pharmaceuticals Appoints Don Hayden to Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 14 Mar 2022
IDEAYA and Pfizer Expand Clinical Trial Collaboration and Supply Agreements for Evaluation of Darovasertib and Crizotinib Combination in Metastatic Uveal Melanoma and Additional cMET-Driven Tumors
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Feb 2022
Biofidelity Raises $23M in Series A+ Financing led by Octopus Ventures to Launch ASPYRE Technology
Diagnostics Oncology Venture Capital
 HSMN NewsFeed - 13 Jan 2022
SK Life Science Announces FDA Clearance of IND Application for its Oncology Candidate, SKL27969, a PRMT5 Inhibitor for the Potential Treatment of Advanced Solid Tumors
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 30 Dec 2021
Blueprint Medicines Completes Acquisition of Lengo Therapeutics
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 29 Nov 2021
Blueprint Medicines to Expand Precision Therapy Leadership in Lung Cancer with Acquisition of Lengo Therapeutics
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 1 Nov 2021
Theseus Pharmaceuticals Announces FDA Clearance of Investigational New Drug Application for THE-630, a Pan-Variant KIT Inhibitor in Development for the Treatment of Gastrointestinal Stromal Tumors (GIST)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 22 Sep 2021
Kintara Reports Topline Results from Phase 2 Clinical Study of VAL-083 as Adjuvant Therapy for Newly-Diagnosed GBM Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 Sep 2021
Sutro Biopharma Announces Expansion of Leadership Team
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 16 Sep 2021
LUMAKRAS(TM) (Sotorasib) Combined With Vectibix(R) (Panitumumab) Showed Encouraging Efficacy And Safety In Patients With KRAS G12C-Mutated Colorectal Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 Aug 2021
Sutro Biopharma Appoints Jane Chung as Chief Commercial Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 11 May 2021
Nuvalent Completes $135 Million Series B Financing to Advance Portfolio of Novel Precisely Targeted Kinase Inhibitors for Treatment-Resistant Cancers
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 4 May 2021
Theseus Pharmaceuticals Appoints Tim Clackson, Ph.D., as Chief Executive Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 19 Apr 2021
Amgen Launches Biomarker Assist(TM), a Program To Help More Patients With Non-Small Cell Lung Cancer Gain Access To Biomarker Testing
Diagnostics Oncology Product Launch
 HSMN NewsFeed - 23 Mar 2021
Nuvalent Appoints Christopher Turner, M.D., as Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 22 Mar 2021
Sutro Biopharma Strengthens Leadership Through Management Promotions and Expansion of Clinical Advisory Board
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 9 Mar 2021
Roche receives FDA approval for VENTANA ALK (D5F3) CDx Assay to identify lung cancer patients eligible for targeted treatment with LORBRENA (lorlatinib)
Diagnostics Oncology FDA
 HSMN NewsFeed - 18 Feb 2021
OncoSec Appoints Bridget O'Keeffe, Ph.D. as Vice President of Clinical Development
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 12 Feb 2021
The Lancet Publishes Libtayo(R) (cemiplimab) Data Showing Extended Overall Survival in Patients with First-line Advanced Non-small Cell Lung Cancer with PD-L1 Expression of ≥50%
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Feb 2021
Actimed Therapeutics Appoints Frank Misselwitz MD, PhD as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 27 Jan 2021
Nuvalent Launches with $50M Series A Financing from Deerfield Management to Develop Precisely Targeted Kinase Inhibitors for Treatment-Resistant Cancers
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 8 Dec 2020
Amgen's Sotorasib Granted Breakthrough Therapy Designation for Advanced or Metastatic Non-Small Cell Lung Cancer Patients with KRAS G12C Mutation
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 29 Oct 2020
Roche receives FDA approval for the cobas EGFR Mutation Test v2 as the first companion diagnostic test for expanded EGFR TKI therapies in patients with non-small cell lung cancer
Diagnostics Oncology FDA
 HSMN NewsFeed - 8 Sep 2020
FDA Approves First NGS-Based Companion Diagnostic for RET Fusion-Positive Non-Small Cell Lung Cancer
Diagnostics Oncology FDA
 HSMN NewsFeed - 25 Aug 2020
FDA Accepts Filing of New Drug Application for Tepotinib for the Treatment of Patients with Metastatic NSCLC with METex14 Skipping Alterations
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 20 Aug 2020
Kintara Therapeutics (Formerly DelMar Pharmaceuticals) Announces Completion of Merger with Adgero Biopharmaceuticals and Closing of $19.6 Million Private Placement Priced At-The-Market
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 18 Aug 2020
Innovent and Lilly Announce Expansion of TYVYT(R) (Sintilimab Injection) Licensing Agreement
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 17 Aug 2020
DelMar Announces Approval of Merger by Stockholders
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 12 Aug 2020
Innovent and Eli Lilly Announce Acceptance of a Supplemental New Drug Application of TYVYT(R) (Sintilimab Injection) in Combination with Gemcitabine and Platinum as First-Line Therapy in Squamous Non-Small Cell Lung Cancer in China
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 26 May 2020
ArcherDX Announces Strategic Collaboration with AstraZeneca to Develop Personalized Cancer Monitoring (PCM) Assays for Minimal Residual Disease (MRD)
Biopharmaceuticals Diagnostics Oncology
 HSMN NewsFeed - 1 Apr 2020
Blueprint Medicines Announces the Achievement of Key Portfolio Milestones
Biopharmaceuticals Oncology
 HSMN NewsFeed - 25 Mar 2020
ArcherDX Receives Approval for Archer(R)MET Companion Diagnostic for TEPMETKO(R) (Tepotinib) in Advanced Non-Small Cell Lung Cancer in Japan
Diagnostics Oncology Regulatory
 HSMN NewsFeed - 25 Feb 2020
KAHR Medical Raises $18 Million in Private Funding Round
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 17 Feb 2020
PharmaMar and Jazz Pharmaceuticals Announce FDA Acceptance and Priority Review of New Drug Application for Lurbinectedin in Relapsed Small Cell Lung Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 11 Feb 2020
Novartis announces MET inhibitor capmatinib (INC280), the first potential treatment for METex14 mutated advanced non-small cell lung cancer, granted priority FDA review
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 29 Jan 2020
Lilly Receives FDA Priority Review for the Selpercatinib New Drug Application
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 22 Jan 2020
PharmaMar and Jazz Pharmaceuticals Announce the U.S. License Agreement for Lurbinectedin is Effective with the Expiration of the HSR Waiting Period
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 30 Dec 2019
Lilly Opens Phase 3 Clinical Trial in RET-Mutant Medullary Thyroid Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 13 Nov 2019
Armas Pharmaceuticals Announces Launch of Oncology Generic Erlotinib
Biopharmaceuticals Generics Oncology Product Launch
 HSMN NewsFeed - 5 Nov 2019
Regeneron Provides Updates on Phase 3 Libtayo(R) (cemiplimab) Development Program in Advanced Non-small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Sep 2019
Merck KGaA, Darmstadt, Germany, Announces FDA Breakthrough Therapy Designation for Investigational Therapy Tepotinib in Patients with Metastatic NSCLC with METex14 Skipping Alterations
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 Sep 2019
Lilly Announces Positive Results for Selpercatinib (LOXO-292), Demonstrating a 68 Percent Objective Response Rate and Sustained Durability in Heavily Pretreated RET Fusion-Positive Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 Sep 2019
Thermo Fisher Scientific Signs Agreement with Lilly Oncology for Companion Diagnostic to be Used with RET Inhibitor
Diagnostics Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 29 Aug 2019
AbbVie Discontinues Rovalpituzumab Tesirine (Rova-T) Research and Development Program
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Aug 2019
Nektar Therapeutics and Bristol-Myers Squibb Announce U.S. FDA Breakthrough Therapy Designation for Bempegaldesleukin (NKTR-214) in Combination with Opdivo(R) (nivolumab) for the Treatment of Patients with Untreated Advanced Melanoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 21 May 2019
DelMar Pharmaceuticals Announces Expansion of Scientific Advisory Board
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 15 May 2019
IO Biotech Initiates Global Phase 2 Portion of Clinical Trial For T-win(R) Immunotherapy in Non-small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 May 2019
Daiichi Sankyo Announces [Fam-] Trastuzumab Deruxtecan Demonstrated Clinically Meaningful Response in Patients with Refractory HER2 Positive Metastatic Breast Cancer, a Population with High Unmet Need
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Apr 2019
DelMar Pharmaceuticals Welcomes Dr. John de Groot, Chairman, ad interim of the Department of Neuro-Oncology at MD Anderson Cancer Center, as founding member of the Company's Scientific Advisory Board
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 26 Feb 2019
Thermo Fisher Scientific's Oncomine Dx Target Test Receives Expanded Regulatory Approval in Japan
Diagnostics Oncology Regulatory
 HSMN NewsFeed - 14 Jan 2019
Daiichi Sankyo Initiates Pivotal Phase 3 Trial of [Fam-] Trastuzumab Deruxtecan (DS-8201) in HER2 Low Metastatic Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 Dec 2018
Merck KGaA, Darmstadt, Germany Announces FDA Orphan Drug Designation for Bifunctional Immunotherapy M7824 in Biliary Tract Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 17 Oct 2018
Thermo Fisher Scientific CE Marks Oncomine Dx Target Test
Diagnostics Oncology Regulatory
 HSMN NewsFeed - 10 Oct 2018
OSE Immunotherapeutics and Oncology Physician Network GERCOR Announce Submission of Investigational New Drug Application to Evaluate Tedopi(R) in Combination with Nivolumab in Pancreatic Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 23 Aug 2018
Roche receives FDA approval for cobas EGFR Mutation Test v2 as companion diagnostic with IRESSA (gefitinib) in first-line treatment of patients with non-small cell lung cancer (NSCLC)
Diagnostics Oncology FDA
 HSMN NewsFeed - 2 Jul 2018
Phase III IMpassion130 Study Showed Genentech's TECENTRIQ Plus Abraxane Significantly Reduced the Risk of Disease Worsening or Death in People With Metastatic or Locally Advanced Triple Negative Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 25 Jun 2018
DelMar Pharmaceuticals Appoints World-Renowned Molecular Biologist Dr. Napoleone Ferrara to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 19 Jun 2018
Alpha Biopharma Announces Series A Financing
Biopharmaceuticals Oncology Venture Capital Personnel
 HSMN NewsFeed - 14 Jun 2018
Apexigen and Yale Cancer Center Announce Clinical Collaboration to Evaluate APX005M, Cabiralizumab, and Opdivo (Nivolumab) in Patients whose Disease has Progressed on Anti-PD-1/PD-L1 Therapy
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Jun 2018
FDA Expands Lilly's ALIMTA(R) (pemetrexed) Label to Include Combination with KEYTRUDA(R) (pembrolizumab) and Carboplatin as First-Line Treatment for Metastatic Nonsquamous Non-Small Cell Lung Cancer, Irrespective of PD-L1 Expression
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 4 Jun 2018
Blueprint Medicines and CStone Pharmaceuticals Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Avapritinib, BLU-554 and BLU-667 in Greater China
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 7 May 2018
Genprex Announces $10 Million Private Placement
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 11 Apr 2018
Genprex Appoints Julien Pham, MD, MPH As President To Lead Commercialization Of Oncoprex Immunogene Therapy
Biopharmaceuticals Oncology Drug Delivery Personnel
 HSMN NewsFeed - 8 Mar 2018
Infinity Pharmaceuticals Announces Additions to Board of Directors and Clinical Leadership Team and Establishes Scientific Advisory Board
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 22 Dec 2017
Novartis' combination therapy Tafinlar(R) + Mekinist(R) granted FDA Priority Review for the adjuvant treatment of stage III BRAF V600 mutation-positive melanoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 10 Nov 2017
Amgen And Allergan Receive Positive CHMP Opinion For ABP 215 (Biosimilar Bevacizumab) For The Treatment Of Certain Types Of Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 7 Nov 2017
Pique Therapeutics Announces Positive Results in Phase 2 Clinical Trial of Lead Immunotherapy for Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Jul 2017
DelMar Pharmaceuticals Appoints Saiid Zarrabian to the Board of Directors and Names Dr. Erich Mohr as Chairman
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 1 Jun 2017
Roche announces FDA approval of companion diagnostic to identify ALK-positive non-small cell lung cancer patients
Diagnostics Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 31 May 2017
Lilly Announces Phase 3 RANGE Urothelial Cancer Trial of CYRAMZA(R) (ramucirumab) Met Primary Endpoint, Improving Progression-Free Survival
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 May 2017
Array BioPharma and Bristol-Myers Squibb Announce Strategic Collaboration
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 Mar 2017
FDA Approves Merck’s KEYTRUDA(R) (pembrolizumab) for Adult and Pediatric Patients with Classical Hodgkin Lymphoma (cHL) Refractory to Treatment, or Who Have Relapsed After Three or More Prior Lines of Therapy
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 20 Jan 2017
Bristol-Myers Squibb Provides Regulatory Update in First-line Lung Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 30 Nov 2016
Celldex Therapeutics Completes Acquisition of Kolltan Pharmaceuticals
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 18 Nov 2016
Athenex and Lilly Enter Clinical Collaboration Agreement
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Nov 2016
Bristol-Myers Squibb’s Opdivo(R) (nivolumab) is the First Immuno-Oncology Treatment to Receive FDA Approval Based on Overall Survival in Head and Neck Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 2 Nov 2016
Turnstone Biologics Raises $41.4 Million Series B Financing
Biopharmaceuticals Oncology Venture Capital Personnel
 HSMN NewsFeed - 25 Oct 2016
Agilent Technologies Receives Expanded FDA Approval for Use of Dako PD-L1 IHC 22C3 pharmDx Companion Diagnostic in Non-Small Cell Lung Cancer (NSCLC)
Diagnostics Oncology FDA
 HSMN NewsFeed - 14 Oct 2016
Bristol-Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab) for the Treatment of Adult Patients With Relapsed or Refractory Classical Hodgkin Lymphoma After Autologous Stem Cell Transplant and Treatment With Brentuximab Vedotin
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 30 Sep 2016
Threshold Pharmaceuticals Announces Interim Results from Tarloxotinib Program and its Plans to Focus on Evofosfamide and Earlier-Stage Opportunities
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 Sep 2016
Prospective, independent study demonstrates the utility of Guardant360 for guiding therapy selection in advanced Non-Small-Cell Lung Cancer
Diagnostics Oncology
 HSMN NewsFeed - 5 Sep 2016
Eisai Bewildered as German Institute for Quality and Efficiency in Health Care (IQWIG) Fails to Recognise Additional Benefit of Halaven(R) (eribulin) in the Treatment of Advanced Liposarcoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 31 Aug 2016
XALKORI(R) (Crizotinib) Receives Approval In European Union For The Treatment Of Patients With ROS1-Positive Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 9 Aug 2016
AstraZeneca Provides Update On Phase III Trial Of Selumetinib In Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Aug 2016
Merck’s KEYTRUDA(R) (pembrolizumab) Approved by the European Commission for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Express PD-L1
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 26 Jul 2016
Janssen Announces Clinical Collaboration with Bristol-Myers Squibb to Evaluate Immuno-oncology Combination in Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 Jul 2016
REVLIMID(R) (Lenalidomide) Approved by the European Commission for the Treatment of Relapsed/Refractory Patients with Mantle Cell Lymphoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 6 Jul 2016
FDA Grants Merrimack Fast Track Designation for Seribantumab (MM-121) in Non-small Cell Lung Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 27 Jun 2016
Merck Receives CHMP Positive Opinion for KEYTRUDA(R) (pembrolizumab) for the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 16 Jun 2016
Merck’s KEYTRUDA(R) (pembrolizumab) Demonstrates Superior Progression-Free and Overall Survival Compared to Chemotherapy as First-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 26 Apr 2016
Hematogenix Laboratory Services, LLC (Hematogenix)- Announces the Launch of two U.S. Food and Drug Administration (FDA) Approved PD-L1 Companion Diagnostic Tests to Help Guide Oncologists Using Immuno-Oncology Therapies
Diagnostics Oncology Product Launch
 HSMN NewsFeed - 11 Apr 2016
FDA Grants Priority Review for Genentech’s Cancer Immunotherapy Atezolizumab in Specific Type of Lung Cancer
Biopharmaceuticals Personalized Medicine Oncology FDA
 HSMN NewsFeed - 17 Mar 2016
Allergan Confirms Generic Abraxane(R) Patent Challenge
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 17 Feb 2016
Catalyst Pharmaceuticals Receives "Refusal to File" Letter From the FDA on Its NDA for Firdapse
Biopharmaceuticals FDA
 HSMN NewsFeed - 16 Feb 2016
Helsinn Group Signs Exclusive Agreement With Mundipharma for the Distribution and Licence of Anamorelin in Northern Europe Countries
Biopharmaceuticals Oncology Licensing Distribution
 HSMN NewsFeed - 29 Jan 2016
Helix BioPharma Corp. Announces Appointment of New Directors to the Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 27 Jan 2016
Boehringer Ingelheim's Gilotrif(R) Demonstrated Superiority to Iressa(R) (Gefitinib) in Reducing the Risk of Disease Progression and Treatment Failure in First-Line Treatment of Patients with EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Jan 2016
CytRx Corporation Appoints Olivia Ware as Chief Commercial Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 16 Dec 2015
BIND Therapeutics Appoints Jonathan Yingling, Ph.D., as Chief Scientific Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 10 Dec 2015
Lilly and Merck Expand Immuno-Oncology Collaboration Adding Abemaciclib and KEYTRUDA(R) Combination Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 7 Dec 2015
Nemucore Medical Innovations Completes Series A Financing
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 25 Nov 2015
Pfizer Receives European Approval to Expand Use of XALKORI(R) (crizotinib) to First-Line Treatment of Adults with ALK-Positive Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 24 Nov 2015
European Commission Approves Reconciliation of Indications for nivolumab Under the Opdivo(R) European Marketing Authorization Application
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 24 Nov 2015
Bristol-Myers Squibb Announces U.S. Food and Drug Administration Approval for Opdivo (nivolumab) as a Single Agent for the Treatment of Patients with Previously Untreated BRAF Wild-Type Advanced Melanoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 18 Nov 2015
Pfizer Reports Positive Topline Results from Phase 3 Trial Comparing XALKORI(R) (crizotinib) to Chemotherapy in Previously Untreated East Asian Patients with ALK-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 Oct 2015
Teikoku Pharma USA and Eagle Pharmaceuticals Enter into License Agreement for Docetaxel, Non-Alcohol Formula
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 15 Oct 2015
Biothera Appoints Dr. Jose Iglesias as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 1 Oct 2015
Bristol-Myers Squibb Receives Approval from the U.S. Food and Drug Administration for the Opdivo (nivolumab) + Yervoy (ipilimumab) Regimen in BRAF V600 Wild-Type Unresectable or Metastatic Melanoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 25 Sep 2015
Merck and Pfizer Announce FDA Orphan Drug Designation for Investigational Immunotherapy Avelumab in Merkel Cell Carcinoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 3 Sep 2015
Helsinn Group Signs Exclusive Agreement With Mundipharma for the Distribution and Licence of anamorelin in Switzerland and Liechtenstein
Biopharmaceuticals Licensing Distribution
 HSMN NewsFeed - 5 Aug 2015
Mirati Therapeutics And MedImmune Partner On Immuno-Oncology Combination In Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 Jul 2015
New TomoTherapy(R) System Data Presented at Leading Scientific Industry Meeting
Devices Oncology
 HSMN NewsFeed - 11 Jun 2015
Personal Genome Diagnostics Launches LungSelect(TM) For Non-Invasive Detection Of Clinically Actionable Mutations In Lung Cancer
Diagnostics Oncology Product Launch
 HSMN NewsFeed - 29 May 2015
Transgenomic Launches EGFR CLIA Test That Accurately Detects Key Mutations in Solid and Liquid Patient Samples Using Multiplexed ICE COLD-PCR(TM)
Diagnostics Oncology Product Launch
 HSMN NewsFeed - 6 May 2015
EMD Serono Initiates Co-Promotion of XALKORI(R) (crizotinib) with Pfizer in the United States
Biopharmaceuticals Oncology Distribution
 HSMN NewsFeed - 24 Apr 2015
Bristol-Myers Squibb Receives Positive CHMP Opinion in the European Union for Opdivo (nivolumab) for the Treatment of Advanced Melanoma in Both First-Line and Previously Treated Patients
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 19 Mar 2015
Coronado Biosciences Announces Exclusive Licensing Agreement With NeuPharma to Develop and Commercialize Novel Covalent 3rd Generation EGFR Inhibitors
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 18 Mar 2015
Hong Kong Authority Approves Abraxane(R) as First-Line Treatment For Late-Stage Pancreatic Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 27 May 2014
Bristol-Myers Squibb and Incyte Enter Clinical Collaboration Agreement to Evaluate Combination Regimen of Two Novel Immunotherapies
Biopharmaceuticals Oncology
 HSMN NewsFeed - 29 Apr 2014
Novartis gains FDA approval for Zykadia(TM), first therapy for patients with ALK+ NSCLC previously treated with the ALK inhibitor crizotinib
Biopharmaceuticals Oncology
 HSMN NewsFeed - 7 Apr 2014
Merck Serono Announces Initiation of Phase III START2 Study with Tecemotide in Stage III Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Apr 2014
GTx Announces Departure of CEO
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 26 Mar 2014
FDA Approves Optiguide(R) DCYL700 Fiber Optic Diffuser Series Flexible Fiber
Devices FDA
 HSMN NewsFeed - 13 Mar 2014
Elekta's Versa HD rapidly enters service as ideal system for stereotactic radiotherapy to treat cancer patients
Devices Oncology
 HSMN NewsFeed - 3 Mar 2014
Genentech Provides Update on Phase III Study of Onartuzumab in People with Specific Type of Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 Feb 2014
Lilly Announces Ramucirumab Phase III Lung Cancer Trial Meets Primary Endpoint of Overall Survival
Biopharmaceuticals Oncology
 HSMN NewsFeed - 27 Jan 2014
Biothera Names VP of Biomarker Development
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 27 Jan 2014
Pfizer Announces Top-Line Results From Two Phase 3 Trials Of Dacomitinib In Patients With Refractory Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 24 Jan 2014
Novocure Enrolls First Patient in Pilot Clinical Trial of NovoTTF(TM) Therapy Plus Gemcitabine for First-line Treatment of Advanced Pancreatic Adenocarcinoma
Devices Oncology
 HSMN NewsFeed - 13 Jan 2014
Agenus Enters into Definitive Agreement to Acquire Privately Held 4-Antibody AG
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 6 Jan 2014
Peregrine Pharmaceuticals Receives FDA Fast Track Designation for Its Immunotherapy Bavituximab as a Potential Treatment of Second-Line Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 24 Dec 2013
Concordia Healthcare Corp. Announces Acquisition Of Pinnacle Biologics, Inc.
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 2 Dec 2013
Biodesix Closes Series E Financing
Diagnostics Personalized Medicine Venture Capital
 HSMN NewsFeed - 27 Nov 2013
Study Suggests Non-Invasive Stereotactic Ablative Body Radiotherapy May Be Suitable Alternative to Surgery for Early-Stage Lung Cancer Patients
Devices Oncology
 HSMN NewsFeed - 19 Nov 2013
Novocure Enrolls First Patients in a Randomized Trial of NovoTTF(TM) Therapy for Patients with Brain Metastases from Non-Small Cell Lung Cancer
Devices Oncology
 HSMN NewsFeed - 6 Sep 2013
U.S. Food and Drug Administration Approves ABRAXANE(R) in Combination with Gemcitabine as First-Line Treatment of Patients with Metastatic Pancreatic Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 5 Sep 2013
GSK’s MAGE-A3 Cancer Immunotherapeutic Phase 3 Study in Melanoma Misses First Co-Primary Endpoint
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 Apr 2013
Lilly Debuts Early Oncology Pipeline Data At AACR Annual Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Mar 2013
Precision Therapeutics Announces Topline Prospective Clinical Data Demonstrating Significant Improvement in Overall Survival and Progression Free Survival in Recurrent Ovarian Cancer using Personalized Chemotherapy Diagnostic ChemoFx(R)
Diagnostics Oncology Personalized Medicine
 HSMN NewsFeed - 28 Nov 2012
Curis Announces Worldwide In-Licensing of IAP Inhibitor GDC-0917 From Genentech
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 12 Nov 2012
Clovis Oncology Announces Negative Outcome of CO-101 in Pivotal LEAP Pancreatic Cancer Study
Biopharmaceuticals Oncology
 HSMN NewsFeed - 24 Oct 2012
Abbott's ALK Test is Now Available in Europe as a Companion Diagnostic Test to Aid in Identifying Patients for Targeted Lung Cancer Therapy
Diagnostics Personalized Medicine Oncology
 HSMN NewsFeed - 12 Oct 2012
FDA Approves ABRAXANE(R) for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 21 Sep 2012
Astex Pharmaceuticals Discontinues Amuvatinib Clinical Development Program
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 Sep 2012
Pfizer To Present New Data in Lung And Kidney Cancers at The European Society For Medical Oncology 2012 Congress
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 Jul 2012
Addition of Tarceva(R) (erlotinib) to Nexavar(R) (sorafenib) did not Provide Additional Benefit to Patients with Unresectable Liver Cancer Versus Nexavar alone in Phase 3 Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 Jul 2012
Biodesix Appoints Vice President of Clinical Development & Medical Affairs
Diagnostics Personalized Medicine Personnel
 HSMN NewsFeed - 26 Jun 2012
Caris Life Sciences Launches Caris Target Now(TM) Select for NSCLC, Melanoma, and Cancers of the Breast, Colon, and Ovary
Diagnostics Oncology
 HSMN NewsFeed - 19 Jun 2012
Pfizer Announces Positive Results From Phase 3 Study PROFILE 1007 Evaluating XALKORI(R) (crizotinib) In Previously Treated Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Jun 2012
Afatinib* delivers unprecedented first line efficacy in patients with EGFR mutation positive lung cancer in registration trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 May 2012
Phase 3 MISSION trial of Nexavar (sorafenib) in Patients with Non-Small Cell Lung Cancer Did Not Meet Primary Endpoint of Improving Overall Survival
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 May 2012
Accuray Unveils Enhanced TomoTherapy Treatment Planning System at ESTRO 31
Devices Oncology
 HSMN NewsFeed - 1 May 2012
Retrospective Study Suggests that Stereotactic Ablative Radiotherapy (SABR) Can be a Viable Option for Treating Early-Stage Lung Cancer in Operable as well as Inoperable Patients; Phase III Randomized Trial Now Under Way
Devices Oncology
 HSMN NewsFeed - 12 Mar 2012
Synta Announces Appointment of Dvorit Samid, Ph.D., as Vice President, Medical Affairs
Biopharmaceuticals Personnel
 HSMN NewsFeed - 28 Oct 2011
ALIMTA First Chemotherapy Approved in Europe as Continuation Maintenance Therapy for Most Common Form of Lung Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 27 Aug 2011
Abbott Receives FDA Approval for ALK Gene Test for Lung Cancer Therapy Selection
Diagnostics Personalized Medicine Oncology FDA
 HSMN NewsFeed - 27 Aug 2011
U.S. Food And Drug Administration Approves Pfizer’s XALKORI(R) (crizotinib) As First And Only Therapy Specifically For Patients With Locally Advanced Or Metastatic ALK-Positive Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 20 Jul 2011
Agennix Hires Christine Boisclair as Senior Vice President of Global Regulatory Affairs
Biopharmaceuticals Personnel
 HSMN NewsFeed - 21 Jun 2011
TESARO Announces $101 Million Series B Financing for Advancement and Expansion of Oncology Product Portfolio
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 3 Jun 2011
Tarceva Nearly Doubled the Time People With a Genetically Distinct Type of Lung Cancer Lived Without Their Disease Getting Worse
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 May 2011
Pfizer Announces Simultaneous Filing Of New Drug Applications For Crizotinib With U.S. Food And Drug Administration And Japanese Ministry Of Health, Labour And Welfare
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Mar 2011
TESARO Enters into Exclusive License Agreement with Amgen to Acquire Rights to Anaplastic Lymphoma Kinase (ALK) Program
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 21 Mar 2011
Cephalon Announces Definitive Agreement to Acquire Gemin X
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 10 Mar 2011
Sanofi-aventis and Regeneron Report Top-line Results from Phase III Study with aflibercept (VEGF Trap) in Second-Line Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Feb 2011
Third Phase III Study of Avastin-Based Regimen Met Primary Endpoint in Ovarian Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Feb 2011
Lilly, Bristol-Myers Squibb Stop Enrollment in One of Two Phase III Lung Cancer Trials of Necitumumab
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 Dec 2010
Genentech Provides Update on Avastin for Metastatic Breast Cancer Following Reviews in Europe and the United States
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 Nov 2010
VeriStrat(R) Test Identifies Lung Cancer Patients Benefiting from Combination Therapy
Diagnostics Personalized Medicine Oncology
 HSMN NewsFeed - 13 Oct 2010
IsoRay's Revolutionary Internal Radiation Therapy for Lung Cancers is Focus of National Study
Devices Oncology
 HSMN NewsFeed - 18 Aug 2010
ImmunoGen, Inc. Announces Orphan Drug Designation Granted to Lorvotuzumab Mertansine for Treatment of Small-Cell Lung Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 4 Aug 2010
Gemin X Closes $8 Million Series E Financing
Biopharmaceuticals Venture Capital Oncology
 HSMN NewsFeed - 30 Jun 2010
Celgene to Acquire Abraxis BioScience Inc.
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 21 Jun 2010
Exelixis Regains Full Rights to Develop and Commercialize XL184
Biopharmaceuticals
 HSMN NewsFeed - 14 Jun 2010
Phase 3 Trial of Nexavar in First-Line Advanced Non-Small Cell Lung Cancer Does Not Meet Primary Endpoint of Overall Survival
Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 May 2010
Neotropix Announces Enrollment of Patients in NCI-Sponsored Phase II Clinical Trial for Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 29 Apr 2010
OSI Pharmaceuticals Announces That Tarceva(R) Received Approval in the European Union for Maintenance Use in Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 20 Apr 2010
Gemin X Announces $16 Million Series D Financing
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 29 Mar 2010
Merck Serono: Erbitux Granted Extended Use in Japan for 1st-Line Treatment of mCRC Patients with KRAS Wild-Type Tumors
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 Mar 2010
Study Reveals TomoTherapy(R) Technology Plays Key Role in Enabling Concurrent Chemo-Radiation Treatments for Lung Cancer
Devices Oncology
 HSMN NewsFeed - 23 Mar 2010
Oncothyreon announces temporary suspension of Stimuvax clinical trials by Merck Serono
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 Mar 2010
OSI Pharmaceuticals Announces That Tarceva(R) Received a Positive Opinion from Health Authorities in the European Union for First-Line Maintenance Use in Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 17 Mar 2010
ABRAXANE Meets Primary Endpoint in Phase 3 Trial for Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 Feb 2010
BSD Medical Reports Publication of Chinese Study Using the BSD-2000 Hyperthermia System to Treat Lung Cancer
Devices Oncology
 HSMN NewsFeed - 15 Jan 2010
FDA Extends Review Period for Tarceva Application for First-Line Maintenance Use in Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 21 Dec 2009
Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex' Late Stage Innovative Treatment for Multiple Oncology Indications
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 17 Nov 2009
Duke University Initiates Study of AEOL 10150 to Measure Compound's Ability to Protect Healthy Tissue in Mice Receiving Chemotherapy and Radiation for Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 Nov 2009
OSI Pharmaceuticals Announces Tarceva to Be Reviewed by the FDA's Oncologic Drugs Advisory Committee for Use as a First-Line Maintenance Therapy in Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 4 Nov 2009
NovaRx Corporation Announces FDA Approval of Protocol Amendment to Special Protocol Assessment (SPA) for Phase III Lucanix(R) Study in Non-Small Cell Lung Cancer (NSCLC)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 30 Oct 2009
Global Phase III Study Results Show Eribulin Meets Primary Endpoint of Overall Survival
Biopharmacetuicals Onocology
 HSMN NewsFeed - 24 Sep 2009
Pfizer Launches Phase 3 Clinical Trial With Novel Alk Inhibitor In Non-Small Cell Lung Cancer Patients With Specific Gene Mutation
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Sep 2009
OSI Pharmaceuticals Initiates Phase III Registration-Oriented Study for OSI-906 in Adrenocortical Carcinoma and Phase I/II Study in Ovarian Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 18 Aug 2009
Avastin Plus Commonly Used Chemotherapies Improved Progression-Free Survival (PFS) in Women with Previously Treated Advanced Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Aug 2009
Results from a Phase 2 Study of ABRAXANE(R) In Combination With Carboplatin Show Clinical Activity in the First Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Aug 2009
New Data from Phase III SATURN Study Showed Tarceva Extended Survival in Patients with Advanced Non-Small Cell Lung Cancer When Used Immediately after Initial Chemotherapy
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 Jul 2009
AstraZeneca Submits New Drug Applications for ZACTIMA(TM) in Second-Line Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 13 Jul 2009
New Data from Phase III SATURN Study Showed Tarceva Improved Overall Survival When Used Immediately After Initial Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 10 Jul 2009
ALIMTA(R) (pemetrexed for injection) First Agent Approved in Europe as Maintenance Therapy for Advanced, Nonsquamous Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 6 Jul 2009
Lilly Receives Fourth FDA Approval for ALIMTA(R) (pemetrexed for injection)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 22 Jun 2009
Merck KGaA Initiates Phase III Study of Stimuvax in Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 Jun 2009
Clarient Launches New Gene Mutation Test to Help Select Therapy for Non-Small Cell Lung Cancer
Diagnostics Oncology
 HSMN NewsFeed - 1 Jun 2009
Bayer and Onyx Initiate Phase 3 Trial of Nexavar in Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Jun 2009
UK's NICE Recommends Use of Erbitux for Metastatic Colorectal Cancer Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 29 May 2009
ALIMTA(R) (pemetrexed for injection) Receives Positive Opinion From CHMP as Maintenance Therapy for Nonsquamous Non-Small Cell Lung Cancer
Biopharmaceuticasl Oncology Regulatory
 HSMN NewsFeed - 5 May 2009
FDA Grants Accelerated Approval of Avastin for Brain Cancer (Glioblastoma) That Has Progressed Following Prior Therapy
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 5 May 2009
Biodesix Advances the Field of Personalized Medicine With the Launch of VeriStrat(R)
Diagnostics Oncology
 HSMN NewsFeed - 24 Apr 2009
Roche Announces Collaboration to Investigate New Treatment Strategy With Tarceva in Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Apr 2009
Phase III C-08 Study of Avastin in Early-Stage Colon Cancer Did Not Meet Primary Endpoint
Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 Apr 2009
Oasmia: FDA Grants Paclical(r) Orphan Drug Designation for Ovarian Cancer in the USA
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 9 Apr 2009
Encouraging Results Published on Use of TomoTherapy in Lung Cancer Treatment
Devices Oncology
 HSMN NewsFeed - 19 Mar 2009
OSI Pharmaceuticals Submits Supplemental New Drug Application to the FDA for Tarceva as a First-Line Maintenance Therapy in Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 4 Feb 2009
Peregrine Pharmaceuticals' Bavituximab Achieves Primary Endpoint in First Stage of Phase II Lung Cancer Study
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 Jan 2009
ImClone Systems and Bristol-Myers Squibb Update the Status of Non-Small Cell Lung Cancer Supplemental Biologics Application Submission for ERBITUX(R)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 8 Dec 2008
ERBITUX® Supplemental Biologics License Application for Advanced Non-Small Cell Lung Cancer Submitted to U.S. Food and Drug Administration
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Dec 2008
NovaRx Appoints Industry Veteran as President and COO
Biopharmaceuticals Personnel
 HSMN NewsFeed - 26 Nov 2008
Tarceva(R) (erlotinib) Endorsed by the U.K.'s National Institute for Health and Clinical Excellence for Use in Patients with Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 Nov 2008
Avastin Plus Commonly Used Chemotherapies Demonstrated Improved Progression-Free Survival In Advanced Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Nov 2008
Genentech Submits Application to U.S. Food and Drug Administration for Avastin in the Most Aggressive Form of Brain Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 Oct 2008
OXiGENE, Inc. Names John A. Kollins as Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 20 Oct 2008
Peregrine Pharmaceuticals Completes Patient Enrollment In First Stage of Bavituximab Phase II Lung Cancer Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Oct 2008
Genentech Announces Phase III Study of Avastin Plus Chemotherapy in Adjuvant Colon Cancer Will Continue
Biopharmaceuticals Oncology
 HSMN NewsFeed - 6 Oct 2008
Lilly to Acquire ImClone Systems in $6.5 Billion Transaction
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 29 Sep 2008
FDA Grants Lilly's ALIMTA(R) (Pemetrexed for Injection) Third U.S. Approval
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 22 Sep 2008
CytRx Corporation Completes Acquisition of Innovive Pharmaceuticals, Inc.
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 4 Sep 2008
Amrubicin Receives FDA Fast Track Designation for the Treatment of Small Cell Lung Cancer after First-Line Chemotherapy
Biopharmaceuticals FDA Oncology
 HSMN NewsFeed - 29 Aug 2008
ERBITUX(R) Phase 3 BMS-099 Lung Cancer Study Secondary Endpoint Update: Overall Survival Results Announced
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Aug 2008
Lung Cancer Epidemic Looming in Asia?
Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 Jul 2008
Radiofrequency Ablation Yields High Proportions of Sustained Complete Responses in Patients with Lung Cancer
Devices Oncology
 HSMN NewsFeed - 7 Jul 2008
Complete Study Results Comparing CTI's OPAXIO(TM) With Gemcitabine or Vinorelbine in Performance Status (PS 2) NSCLC Patients Published in Journal of Thoracic Oncology
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 Jun 2008
CytRx Corporation Signs Definitive Agreement to Acquire Innovive Pharmaceuticals, Inc.
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 31 May 2008
ERBITUX(R) (Cetuximab) Data Demonstrate Improved Overall Survival in First-Line Treatment of Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 31 May 2008
Amgen Presents New Data at ASCO on Four Investigational Molecules from Oncology Pipeline
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 May 2008
New Data on MAGE-A3 Cancer Immunotherapy Support Potential Novel Options of Treating Non-Small Cell Lung Cancer and Melanoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 May 2008
Study Showed ALIMTA(R) (pemetrexed for injection) Improved Survival in Certain Types of Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 May 2008
ASCO Study Confirms Importance of Histology in Treatment of Non-Small Cell Lung Cancer With ALIMTA (pemetrexed for injection)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 May 2008
European Regulatory Agency Supports OPAXIO(TM) Brand Name for Cell Therapeutics' Lung Cancer Drug
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 28 Apr 2008
Alfacell Announces Retirement of Chief Executive Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 21 Apr 2008
Genentech Provides Update on ''AVAiL'' Phase III Study of Avastin Plus Chemotherapy in First-Line, Advanced, Non-Squamous, Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Apr 2008
Amrubicin is Designated as an Orphan Medicinal Product by the European Commission for the Treatment of Small Cell Lung Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 11 Apr 2008
ALIMTA(R) (pemetrexed for injection) Receives European Approval for Histologically-Based Use in First-Line Treatment of Most Common Lung Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 2 Apr 2008
Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Apr 2008
European Regulatory Agency Accepts Cell Therapeutics, Inc.'s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 25 Mar 2008
Amrubicin(R) Receives FDA Orphan Drug Designation for the Treatment of Small Cell Lung Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 18 Mar 2008
BioNumerik Pharmaceuticals and ASKA Pharmaceutical Co. Announce Results from Phase III Clinical Trial of Tavocept(TM)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 13 Mar 2008
EntreMed Announces 2008 Corporate and Clinical Program Priorities
Biopharmaceuticals Oncology
 HSMN NewsFeed - 13 Mar 2008
Novelos Therapeutics Reaches Target Enrollment in Pivotal Phase 3 Lung Cancer Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Mar 2008
AstraZeneca Completes Enrollment in Two Pivotal Phase III Studies of the Investigational Drug Vandetanib (ZACTIMA(R)) in Non-Small Cell Lung Cancer (NSCLC)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 7 Mar 2008
Abbott to Collaborate With Genentech, Roche and OSI on Molecular Test for Lung Cancer Therapy Response
Diagnostics Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Mar 2008
Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 23 Feb 2008
FDA Grants Accelerated Approval of Avastin in Combination With Paclitaxel Chemotherapy for First-Line Treatment of Advanced HER2-Negative Breast Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 18 Feb 2008
Bayer and Onyx Provide Update on Phase 3 Trial of Nexavar in Patients With Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Feb 2008
Infinity and MedImmune Announce Approval for Generic Name for Novel Hsp90 Inhibitor
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Jan 2008
Alfacell Announces ONCONASE(R) Distribution and Marketing Agreement With BL&H for South Korea, Taiwan and Hong Kong
Biopharmaceuticals Distribution Oncology
 HSMN NewsFeed - 17 Jan 2008
Alfacell Appoints David Sidransky Chairman of the Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 Jan 2008
Strativa Pharmaceuticals Acquires Commercialization Rights to Onconase(R) from Alfacell Corporation
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 21 Dec 2007
Pharmacyclics Receives Non-Approvable Letter from the FDA for Xcytrin for the Treatment of Lung Cancer Brain Metastases
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 19 Dec 2007
Avastin Approved in Europe for First-Line Treatment of Patients With Advanced Kidney Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 18 Dec 2007
Cell Therapeutics, Inc. (CTI) to Submit Marketing Authorization Application for XYOTAX(TM) for First-line Non-small Cell Lung Cancer Ahead of Schedule
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 14 Dec 2007
OSI Pharmaceuticals Announces Launch Date of Tarceva(R) (erlotinib) in Japan
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 20 Nov 2007
Alfacell Appoints Lawrence A. Kenyon Chief Operating Officer and Director
Biopharmaceuticals Personnel
 HSMN NewsFeed - 19 Nov 2007
Celgene to Acquire Pharmion for $2.9 Billion in Cash and Stock
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 9 Nov 2007
Pharmion's Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Nov 2007
Amgen Announces Updates to the U.S. Prescribing Information for ESAs
Biopharmaceuticals FDA
 HSMN NewsFeed - 24 Oct 2007
Studies Showing Significant Survival Improvement with Taxotere(R)-based Regimens in the Induction Treatment of Patients with Locally Advanced Head and Neck Cancer are Published in the Same Issue of the New England Journal of Medicine
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 Oct 2007
NCCN Updates Non-Small Cell Lung Cancer Guidelines
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Oct 2007
Tarceva(R) (erlotinib) Earns Approval for Lung Cancer Patients in Japan
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 17 Oct 2007
Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 17 Oct 2007
Pharmion Initiates Pivotal Phase 3 Study of Amrubicin in Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 26 Sep 2007
CuraGen Appoints Clinical Oncologist as VP of Medical Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 25 Sep 2007
Studies Suggest Key Correlation Between Lung Cancer Subtype and Treatment Outcomes
Biopharmaceuticals Oncology
 HSMN NewsFeed - 24 Sep 2007
Progen Announces PI-88 Phase 2 Lung Cancer Results
Biopharmaceuticals Oncology
 HSMN NewsFeed - 24 Sep 2007
Cell Therapeutics, Inc. (CTI) Receives SPA Approval from FDA and Launches Gender-Specific Phase III Trial for Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Sep 2007
Newly Published Phase II Study Shows the Investigational Drug Vandetanib Prolongs Progression-Free Survival in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
Biopharmacetuicals Oncology
 HSMN NewsFeed - 20 Sep 2007
Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 18 Sep 2007
OSI Pharmaceuticals Announces Patent Term Extension for Tarceva(R) (erlotinib)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Sep 2007
Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Sep 2007
ERBITUX(R) Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study
Biopharmaceuticals Oncology
 HSMN NewsFeed - 7 Sep 2007
OSI Pharmaceuticals Summarizes Data Presented on Tarceva(R) (erlotinib) at the 12th World Congress on Lung Cancer Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 6 Sep 2007
Aranesp(R) Study Showing No Negative Impact on Survival in SCLC Presented at World Conference on Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 6 Sep 2007
Pfizer Oncology Initiates Global Phase III Trial to Evaluate Sunitinib Malate Combined with Erlotinib in Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Sep 2007
Pharmacyclics Announces Encouraging Phase 2 Data With Xcytrin(R) in Recurrent Non-Small Cell Lung Cancer Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Sep 2007
Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Sep 2007
Roche's Tarceva(R) Delivers Longer Life for Lung Cancer Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Sep 2007
Study Published in Clinical Cancer Research Confirms Potential Of Peregrine's Bavituximab Combined With Radiation In Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Sep 2007
Poniard Pharmaceuticals Announces Updated Results of Picoplatin Phase 2 Trial Demonstrating Survival Benefit in Small Cell Lung Cancer Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 27 Aug 2007
Nexavar Significantly Improved Overall Survival in Phase 3 Asia-Pacific Liver Cancer Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 Aug 2007
Phase 3 Oncology Program for Aflibercept (VEGF Trap) Initiated by Regeneron and sanofi-aventis
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Aug 2007
Paper in International Journal of Oncology Reports Alfacell's ONCONASE(R) Suppresses Intracellular Oxidative Stress
Biopharmaceuticals Oncology
 HSMN NewsFeed - 26 Jul 2007
Alfacell and US Pharmacia Announce ONCONASE(R) Distribution Agreement for Eastern Europe
Biopharmaceuticals Distribution
 HSMN NewsFeed - 12 Jul 2007
Data Available From ERBITUX(R) Phase III Study in First-Line Treatment of Advanced Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 7 Jun 2007
Biodesix, Inc. Announces Breakthrough In Molecular Diagnostics For Lung Cancer
Diagnostics Oncology
 HSMN NewsFeed - 5 Jun 2007
Extensive Clinical Data on ERBITUX(R) Presented at the 2007 ASCO Annual Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Jun 2007
Encouraging Clinical Activity of GSK's Novel Cancer Immunotherapeutic Confirmed in Phase II Study in Patients with Most Common Form of Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Jun 2007
OSI Pharmaceuticals Summarizes Data on Tarceva(R) (erlotinib) at the 2007 American Society of Clinical Oncology (ASCO) Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Jun 2007
XYOTAX(TM) More Cost Effective With Fewer Side Effects Than Gemcitabine or Vinorelbine in Treating Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Jun 2007
New Study Shows Doxorubicin Plus Paclitaxel Followed by Weekly Paclitaxel as Adjuvant Therapy for High Risk Breast Cancer Warranted in Place of Doxorubicin Plus Cyclophosphamide Followed by Paclitaxel
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Jun 2007
New Data Shows Promising Antitumor Activity with nab-paclitaxel (ABRAXANE(R)) in Combination and as a Single Agent for the Treatment of Lung and Ovarian Cancers
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Jun 2007
Pharmion's Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Jun 2007
Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Jun 2007
New Data Show Pfizer's Axitinib Prolonged Overall Survival in Advanced Pancreatic Cancer When Combined with Standard of Care Chemotherapy
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Jun 2007
Introgen Announces Positive Phase 2 Clinical Trial Results with INGN 225 Immunotherapy in Patients with Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Jun 2007
Survival Benefit Demonstrated in Placebo-Controlled Trial in Patients with Refractory Non-Small Cell Lung Cancer Treated with Agennix's Oral Talactoferrin
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Jun 2007
Pre-menopausal Estrogen Levels Linked to Higher Death Rate Among Women Receiving Chemotherapy for Advanced Non-Small Cell Lung Cancer (NSCLC)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Jun 2007
Nexavar Significantly Extends Overall Survival by 44% in Liver Cancer Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Jun 2007
Telik Announces Top-Line Results of TELCYTA(R) ASSIST-2 Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Jun 2007
ImmunoGen, Inc. Announces Clinical Data Reported at ASCO
Biopharmaceuticals Drug Delivery Oncology
 HSMN NewsFeed - 3 Jun 2007
Study Presented at ASCO Shows Encouraging One-Year and Overall Survival Results for Phase I/II Trial of OGX-011 in Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Jun 2007
Exelixis Reports Integrated Data From Phase II Clinical Trials of XL999 at ASCO
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Jun 2007
Poniard Pharmaceuticals Announces Results of Picoplatin Phase 2 Trial That Confirm and Extend Survival Benefit in Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Jun 2007
Pharmacyclics Announces Positive Final Results of Phase 2 Trial of Xcytrin(R) Plus Radiosurgery for Brain Metastases With Occult Tumors Detected in 24% of Patients
Biopharmaceuticals Devices Oncology
 HSMN NewsFeed - 3 Jun 2007
Xanthus Announces Phase 1 Results for P2045 - a Targeted Agent for Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Jun 2007
New Data Evaluating SUTENT, CP-751,871 and Axitinib in Patients with Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Jun 2007
Clinical Data Suggest Potential Versatility of ALIMTA(R) (Pemetrexed for Injection)-Based Regimens in Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Jun 2007
Study Supports Activity of GEMZAR(R) (Gemcitabine HC1 for Injection) in the Treatment of Early-Stage Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Jun 2007
Targeted, Oral Agent Enzastaurin Shows Favorable Results in Late-Stage Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Jun 2007
Second Phase III Study of Avastin Plus Chemotherapy Shows Improved Progression-Free Survival in First-Line Non-Squamous, Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 30 May 2007
New Data Highlighting ABRAXANE as Single Agent and in Combination for the Treatment of Breast, Lung and Ovarian Cancers to Be Presented at ASCO
Biopharmaceuticals Drug Delivery Oncology
 HSMN NewsFeed - 21 May 2007
Talabostat Clinical Program Put on Clinical Hold by FDA
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 May 2007
Point Therapeutics Announces Interim Analysis to be Performed on Its Phase 3 Talabostat with Alimta Study
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 May 2007
Poniard Pharmaceuticals Appoints Ronald A. Martell President and Chief Operating Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 25 Apr 2007
OSI Pharmaceuticals Announces Pivotal Phase III Tarceva(R) Study Published in the Journal of Clinical Oncology Showed Survival Improvement in Patients with Pancreatic Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 24 Apr 2007
Exelixis Reinitiates Clinical Development of XL999 in Patients With Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 Apr 2007
Pharmacyclics Announces FDA Filing of New Drug Application for Xcytrin(R) Injection to Treat Lung Cancer Brain Metastases
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 Apr 2007
Aranesp(R) ``145 Study'' Shows No Difference in Survival in Patients with Small-Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 18 Apr 2007
GANYMED Raises Euro 33.7 Million in Series C Financing Round
Biopharmaceuticals Oncology Venture Capital
 HSMN NewsFeed - 18 Apr 2007
ONCONASE(R) has Potential as Chemopreventive Agent in Mesothelioma, Reports World-Renowned Mesothelioma Researcher at AACR Annual Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 Apr 2007
Cyclacel Pharmaceuticals Reports Preclinical Seliciclib-Erlotinib Synergy Data at AACR
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 Apr 2007
YM BioSciences' partner Daiichi Sankyo receives clearance for initial clinical trial in Japan
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 15 Apr 2007
Lilly Oncology Focused on Pharmacogenomics at AACR Annual Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Apr 2007
Cell Therapeutics, Inc. (CTI) Announces XYOTAX(TM) Has Fast Track Designation for Women With Advanced Lung Cancer Who Are Performance Status 2 (PS2)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 10 Apr 2007
Coley Pharmaceutical Group Announces Completion of Patient Enrollment in Pfizer's Two Pivotal Phase III NSCLC Clinical Trials
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Apr 2007
Researchers Identify Intracellular Pathway of Alfacell's ONCONASE(R)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Apr 2007
Pharmacyclics' Xcytrin New Drug Application for Treatment of Lung Cancer Brain Metastases to Be Filed Over Protest
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 22 Mar 2007
Studies Show Mild Hyperthermia Enhances Antitumor Effects of Alfacell's ONCONASE(R)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Mar 2007
Cell Therapeutics Inc. (CTI) Files for Special Protocol Assessment (SPA) for XYOTAX(TM) PGT307 Lung Cancer Trial in Women
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 1 Mar 2007
Point Therapeutics Provides Clinical Update
Biopharmaceuticals Oncology
 HSMN NewsFeed - 26 Feb 2007
AstraZeneca Announces New Phase III Study of Vandetanib (ZACTIMA(R), ZD6474) in Patients With Advanced Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 26 Feb 2007
First patient enrolled in Stimuvax(R) Phase III clinical trial in patients with non-small cell lung cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Feb 2007
Analysis of International Phase III Study of Avastin(R) Plus Chemotherapy Shows Improved Progression-Free Survival in Patients With Advanced Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 31 Jan 2007
Alfacell Appoints David Sidransky M.D. as Vice Chairman and Lead Independent Director
Biopharmaceuticals Personnel
 HSMN NewsFeed - 29 Jan 2007
OSI Pharmaceuticals Announces European Regulatory Approval of Tarceva(R) for Treatment of Patients with Pancreatic Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 23 Jan 2007
Safety Monitoring Board Recommends Continuation of EntreMed's MKC-1 Phase 2 Breast Cancer Study
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 Jan 2007
Alfacell Appoints Lawrence A. Kenyon as Executive Vice President, Chief Financial Officer and Corporate Secretary
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 16 Jan 2007
Vicus Therapeutics Announces the FDA has Allowed the Phase 2 Trial of VT-122 for the Treatment of Cachexia in Patients With Advanced Lung Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 10 Jan 2007
Cell Therapeutics, Inc. (CTI) Files for Special Protocol Assessment (SPA) With FDA for XYOTAX Lung Cancer Trial in Women
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Jan 2007
Poniard Pharmaceuticals Receives Special Protocol Assessment for Pivotal Phase 3 Trial of Picoplatin for Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 2 Jan 2007
Stimuvax(R) Phase III clinical trial in patients with non-small cell lung cancer now open for patient enrollment
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 Dec 2006
Pharmacyclics Submits New Drug Application for Xcytrin for the Treatment of Lung Cancer Brain Metastases
Biopharmaceuticals Oncology
 HSMN NewsFeed - 21 Dec 2006
Alfacell Corporation Files for U.S. Orphan Drug Designation for ONCONASE(R)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 20 Dec 2006
Alfacell Corporation and GENESIS Pharma S.A. Announce Exclusive Licensing Agreement for ONCONASE in Southeast Europe
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 15 Dec 2006
OSI Pharmaceuticals Announces That Tarceva(R) Received Positive Opinion from Health Authorities in European Union for the Treatment of Patients with Pancreatic Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 13 Dec 2006
New England Journal of Medicine Publishes Data from Pivotal Study of Avastin Plus Chemotherapy in Most Common Type of Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 13 Dec 2006
Cyclacel Submits IND of CYC116 an Aurora Kinase and VEGRF2 Inhibitor to Treat Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 12 Dec 2006
INNOVIVE Pharmaceuticals Presents Data on Oncology Drug Programs in Chronic Myelogenous Leukemia and Acute Myelogenous Leukemia at American Society of Hematology 48th Annual Meeting
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Dec 2006
Biomira receives special protocol assessment from the FDA for Phase III trial of Stimuvax for non-small cell lung cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 12 Dec 2006
Interim Analysis of Phase III Trial Shows Avastin Plus Interferon Therapy Improved Progression-Free Survival in Patients With Previously Untreated Advanced Renal Cell Carcinoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Dec 2006
Phase III Trial of Nexavar in Patients with Advanced Melanoma Does Not Meet Primary Endpoint
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Nov 2006
Pharmacyclics Announces Presentation of Pooled Analysis of Xcytrin(R) for Lung Cancer Brain Metastases
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 Nov 2006
Study Reinforces Potential Utility of ONCONASE(R) in Non-Small-Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 15 Nov 2006
Pharmion Acquires Cabrellis Pharmaceuticals, Gains Rights to Amrubicin for North America and the European Union
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 9 Nov 2006
Alfacell Corporation Announces Retirement of CFO, Robert D. Love
Biopharmaceuticals Personnel
 HSMN NewsFeed - 6 Nov 2006
Updated Analysis Demonstrates Long-Term Survival Benefit of EFAPROXYN(TM) in Treating NSCLC Patients Receiving Sequential Chemoradiotherapy
Biopharmaceuticals Oncology
 HSMN NewsFeed - 6 Nov 2006
Poniard Announces Positive Interim Survival Results from Ongoing Phase 2 Trial of Picoplatin for Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Nov 2006
Cell Therapeutics, Inc. (CTI) Temporarily Suspends Enrollment on PIONEER Lung Cancer Clinical Trial; Current Patients Continue to Be Treated
Biopharmaceuticals Oncology
 HSMN NewsFeed - 25 Oct 2006
EntreMed Commences Clinical Trial for MKC-1 in Lung Cancer Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 24 Oct 2006
Further Analysis of Phase III Data Using CALGB and EORTC Paradigms Reinforces Survival Benefits of ONCONASE(R) for the Treatment of Patients with Mesothelioma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Oct 2006
Lilly Launches Phase III 'GALES' Trial of ALIMTA(R) (Pemetrexed for Injection) in Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 18 Oct 2006
Taxotere(R) Receives U.S. FDA Approval for the Treatment of Patients With Head and Neck Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 11 Oct 2006
FDA Approves Avastin(R) in Combination With Chemotherapy for First-Line Treatment of Most Common Type of Lung Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 5 Oct 2006
Agennix Receives FDA Fast Track Designation for Talactoferrin Alfa in Non-Small Cell Lung Cancer and Diabetic Foot Ulcers
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 21 Sep 2006
OSI Pharmaceuticals Launches Study of Tarceva(R) as Adjuvant Treatment for Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 19 Sep 2006
Poniard Pharmaceuticals Expands Picoplatin Agreement to Include Exclusive Worldwide Rights and Improved Financial Terms and Conditions
Biopharmaceuticals Licensing
 HSMN NewsFeed - 18 Sep 2006
Cell Therapeutics Inc. Announces Worldwide License and Co-Development Agreement for Development and Commercialization of XYOTAX(TM), an Investigational Agent for Treatment of Women with Non-small Cell Lung Cancer and Other Cancers
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 23 Jul 2006
Nexavar(R) Approved by European Commission for the Treatment of Advanced Kidney Cancer
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 27 Jun 2006
New Research Findings Published in National Academy of Sciences Journal Show Unique Promise of ONCONASE in the Prevention and Treatment of Mesothelioma and Lung Cancer Caused by Asbestos
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Jun 2006
Cell Therapeutics, Inc. (CTI) and FDA Agree on NDA Filing Strategy for XYOTAX(TM)
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 1 Jun 2006
Point Therapeutics Receives Fast Track Designation for Talabostat
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 30 May 2006
Novelos Therapeutics Finalizes SPA with FDA for Phase 3 Trial in Lung Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 24 May 2006
GlaxoSmithKline Demonstrates Progress of Oncology Portfolio; New Data to Be Presented at ASCO 2006
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 May 2006
Recruitment to Resume in Avastin International Phase III Trial (AVANT) in Early-Stage Colon Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 22 May 2006
Hana Biosciences Receives Orphan Drug Designation for Talotrexin (PT-523), For the Treatment of Acute Lymphoblastic Leukemia
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 18 May 2006
Alfacell Corporation To Launch New Program to Explore Potential of ONCONASE(R) to Prevent Mesothelioma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 May 2006
Pharmacyclics to Submit New Drug Application for Xcytrin(R) for Treatment of Lung Cancer Patients With Brain Metastases
Biopharmaceuticals Oncology
Return to NewsFeed  

 Additional items found! 287

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 287 additional stories matching:
SCLC
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.